Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Second phase II trial of razuprotafib to prevent and treat the severe respiratory distress in COVID-19 patients

Next Previous
X
Search
Trial Profile

Second phase II trial of razuprotafib to prevent and treat the severe respiratory distress in COVID-19 patients

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Razuprotafib (Primary)
  • Indications COVID 2019 infections; Respiratory distress syndrome
  • Focus Therapeutic Use
  • Sponsors Aadi Bioscience; Aerpio Pharmaceuticals

    • Most Recent Events

    • 12 Aug 2020 According to an Aerpio Pharmaceuticals media release, trial start up activities are progressing rapidly.
    • 06 Aug 2020 New trial record
    • 04 Aug 2020 According to an Aerpio Pharmaceuticals media release, the company in partnership with Medical Technology Enterprise Consortium, will initiate second COVID-19 trial. MTEC will provide up to $5.1 million in funding toward the clinical trial. Aerpio will support the trial with in kind spending in the amount of $2.8 million.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top